YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, reported a wider net loss for the second quarter ended June 30, 2026, primarily reflecting research and develop…
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the best biotech stocks on this list. TheFly reported on June 15 that UBS initiated coverage of JBIO wit…
(RTTNews) - Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and…
[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Thursday. Stock index futures (SPX [https://seekingalpha.com/symbol/SPX]) were mixed before the bell on…
Jade Biosciences (JBIO [https://seekingalpha.com/symbol/JBIO]) has announced the pricing of a public offering [https://seekingalpha.com/pr/20539889-jade-biosciences-announces-pricing-of-public-offering-of-common-stock] of 10M shares of its…
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company, priced a public offering of 10 million shares at $15.00 per share. The gross proceeds to Jade from the offering are expected to be $150.0 million. Jade's le…
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for auto…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, suggesting potential breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket…
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoi…
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, on Tuesday announced that its first participant has been dosed in the JUNIPER Phase 2 study to evalu…
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data demonstrated dose-depen…
Avidity Partners Management disclosed a buy of 259,700 shares of Enliven Therapeutics(NASDAQ:ELVN) in its May 13, 2026, SEC filing, an estimated $7.19 million transaction based on quarterly average pricing. What happened According to a SEC…
Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 milli…
On May 13, 2026, Avidity Partners Management disclosed a new position in Aktis Oncology(NASDAQ:AKTS), acquiring 468,566 shares in the first quarter. The estimated transaction value was $9.10 million based on quarterly average pricing. What…
In the small-cap biotech space, the biggest opportunities often come from companies working on breakthrough therapies in large, underserved markets. Here are two small-cap stocks that could be compelling high-risk and high-upside investmen…
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027JADE201, a half-life extende…
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm identified the company as being strate…
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.P.…
Jade Biosciences JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary dat…
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in…
Jade Biosciences SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class…
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for aut…
Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.Jade Biosciences (JBIO): Analyst Lauds Entry into Market On November 25, Clear Street analyst Kaveri Pohlman initiated coverage of…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Warner Bros Discovery Inc (Symbol: WBD), where a total of 175,831 contracts have traded so far, representing approximately 17.6 mi…
* Jade Biosciences, Inc. press release [https://seekingalpha.com/pr/20307339-jade-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (JBIO [https://seekingalpha.com/symbol/JBIO]): Q3 GAAP EPS of -$0.48…
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for aut…
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announce…
Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclona…
* Jade Biosciences (NASDAQ:JBIO [https://seekingalpha.com/symbol/JBIO]) has entered into a private placement resulting in gross proceeds of approximately $135 million to the Company. * The company is selling an aggregate of (i) 13,368,164…
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneou…
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for aut…
Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the po…
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announce…
Key Points Jade Biosciences reported a net loss per share of $0.86 (GAAP) for Q2 2025. The company missed analyst GAAP EPS estimates by $0.43, with the net loss per share widening significantly year over year. Research and development spen…
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to…
Investing.com - Jefferies initiated coverage on Jade Biosciences (NASDAQ:JBIO), currently trading at $9.82 with a market cap of $317 million, with a Buy rating and a $16.00 price target on Monday. According to InvestingPro data, analysts’…